The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. immunology market.” “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb).

Portfolios 69

Portfolios Injections Office Safety 69

The Dermatology Digest

APRIL 23, 2024

The CRL did not identify any deficiencies related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical data to support the approval of pz-cel.

Marketing 36

Marketing Safety Clinic Sustainability 36

The Dermatology Digest

NOVEMBER 14, 2024

Regulatory filings in other markets are underway. In addition, the Swiss approval is supported by the results from the head-to-head DELTA FORCE Phase 3 clinical trial, which evaluated the efficacy and safety of delgocitinib cream compared with oral alitretinoin capsules. The cream is fast-tracked by the U.S. .”

Marketing 36

Marketing Eczema Safety Clinic 36

The Dermatology Digest

FEBRUARY 26, 2024

Marketing Authorization Application. The number of patients, the straightforward trial design, the similarity of protocol to the Phase 2 trial, and the identification of the HS dose, collectively, enhance the clarity of SLK’s clinical development and displays promise for the HS franchise.

Office 74

Office Clinic Safety Innovations 74

The Dermatology Digest

FEBRUARY 8, 2024

Jashin Wu, MD, founder and CEO of the Dermatology Research and Education Foundation in San Diego, CA, says that more psoriasis patients will see improvements in their condition due to the influx of new agents and biosimilars on the market. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

AAAMS

DECEMBER 19, 2024

For healthcare professionals seeking a fresh challenge , aesthetic medicine offers a perfect blend of clinical expertise, artistic precision, and patient care. Understanding patient safety protocols and treatment planning. Build and Market Your Practice Once youre trained and certified, its time to start building your practice.

Social Media 52

Social Media Work-Life Balance Training Microneedling 52

The Dermatology Digest

FEBRUARY 27, 2024

While both low-concentration and high-concentration strength biosimilars of Humira are marketed in the U.S. We strongly believe that biosimilars are important in addressing inflationary pressures in the healthcare system across all markets, especially in the U.S. Both Alvotech and Teva expect to launch SIMLANDI in the U.S.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Eco Well Blog

JUNE 14, 2024

Or are they putting these guides out as a fear marketing campaign to promote the EWG seal program (which makes them money)? But hopefully it gives you the gist of why it’s unreliable and why I’ve come to the conclusion that these guides are part of a greater marketing campaign by the EWG. market while tests are still being conducted.

Sun Protection 52

Sun Protection Ingredients Safety Marketing 52

AAAMS

DECEMBER 19, 2024

This foundational knowledge is critical for practitioners who wish to perform aesthetic procedures with precision, confidence, and a commitment to patient safety. Our facial aesthetics program provides a detailed understanding of facial anatomy, physiognomy, and essential techniques, such as Botox and dermal filler injections.

Medical 52

Medical Networking Ethics Surgery 52

The Dermatology Digest

FEBRUARY 16, 2024

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

NIMA Institute

JUNE 30, 2023

Safety and Ethical Practices: Nima places a strong emphasis on safety and ethical practices in Botox and filler administration. Nima’s commitment to safety ensures that you are equipped with the knowledge and skills to prioritize the well-being of your patients and deliver optimal outcomes.

Training 52

Training Medical Esthetics Ethics Esthetics 52

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. The approval is based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. This marks the fourth FDA-approved biosimilar for Stelara.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

JUNE 14, 2024

Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD. ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

MAY 23, 2024

Bimekizumab-bkzx (Bimzelx, UCB) consistently showed sustained improvements in clinical and patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa (HS), according to results from the Phase 3 BE HEARD I and BE HEARD II trials. Bimekizumab-bkzx is an interleukin (IL)-17A and IL-17F inhibitor.

Sustainability 36

Sustainability Safety Clinic Medical 36

New Age Spa Institute

DECEMBER 18, 2024

In this blog, well build upon our discussion of licensure versus certification and explore the different classifications of certifications in esthetics and cosmetology, including Clinical Aesthetics and Master Clinical Aesthetics. Clinical Aesthetics Certification Who is this for? What Are Certifications? Want more info?

Medical 52

Medical Esthetics Legal Continuing Education 52

The Dermatology Digest

FEBRUARY 13, 2024

MediWound Ltd’s EscharEx bested market leader collagenase Santyl ointment in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU). The safety profile and overall incidence of adverse wound reactions were comparable between arms. days for EscharEx vs. 76.0

Safety 36

Safety Marketing Office Clinic 36

New Age Spa Institute

NOVEMBER 20, 2024

Certifications are typically focused on specific skills, such as makeup artistry, clinical aesthetics, or advanced techniques in skincare. Career opportunities for licensed massage therapists are diverse, spanning from spas to clinical settings, such as chiropractic offices and hospitals.

Esthetics 52

Esthetics Therapy Continuing Education Continuous Education 52

The Dermatology Digest

MAY 15, 2024

Torii) to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH (cantharidin) for the treatment of common warts. If positive, the data from this global Phase 3 clinical trial would not only potentially allow Verrica to submit a supplemental new drug application (sNDA) in the U.S. Verrica Pharmaceuticals Inc.

Pharmaceutical 36

Pharmaceutical Clinic Sales Dermatology 36

AAAMS

DECEMBER 9, 2022

the world’s premier corporate consulting firm and the definitive source for all things business, recently devoted an in-depth article to the rapid growth of the global aesthetic medicine market size. Explore current and upcoming aesthetic medicine trends, common procedures and more to learn how you can capitalize on this thriving market.

Chemical Peels 52

Chemical Peels Injections Marketing Networking 52

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

JANUARY 4, 2024

The BLA submission for DMB-3115 is based on results from phase III multi-regional clinical trials in patients with plaque psoriasis, in which the primary endpoint was the rate of change in the Psoriasis Area and Severity Index (PASI) for skin symptoms. market during the next five years. commercialization.

Pharmaceutical 36

Pharmaceutical Partnerships Clinic Safety 36

The Dermatology Digest

JULY 10, 2024

Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab. Eli Lilly and Company recently announced that the U.S.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

New Age Spa Institute

OCTOBER 3, 2024

At New Age Spa Institute, we introduce safer, prostaglandin-free options in our curriculum and continuing education classes like Master Clinical Aesthetics. For those ready to dive deeper, our Eyelash Extension Certification course provides a comprehensive look into lash extension application, maintenance, and safety. </p>

Continuing Education 52

Continuing Education Continuous Education Lash Extensions Makeup 52

AAAMS

MAY 9, 2024

These programs usually combine theoretical knowledge with hands-on clinical experience to ensure that nurses are skilled in delivering safe and effective aesthetic treatments. Nurses were first taught the importance of maintaining a clean and sterile environment, with safety being the top priority.

Training 52

Training Technology Ethics Injections 52

The Dermatology Digest

APRIL 23, 2021

DAXI will get an approval, most likely, for the longest acting toxin that we’ve had on the market.” In anticipation of this longer lasting duration, other brands are clinically testing higher doses for safety, efficacy, and patient satisfaction.

Injections 36

Injections Safety Clinic Branding 36

New Age Spa Institute

JUNE 8, 2023

INGLOT is not exclusively marketed as a “clean beauty” brand, but Inglot Cosmetics emphasizes certain aspects of clean beauty in its formulations and practices. INGLOT places importance on ingredient safety, ethical practices and sustainability. They also offer a wide selection of vegan and cruelty-free cosmetic options.

Makeup 52

Makeup Training Esthetics Hydration 52

Lipgloss and Aftershave

OCTOBER 30, 2024

Unlike large laser companies that spend millions on marketing with big events, influencer partnerships, and doctor endorsements, we avoid these costly strategies, which often contribute to significant price markups. Question Are all of your lasers good for all Fitzpatricks? With a handpiece that is guaranteed to offer over 50 million Shots.

Hair Removal 52

Hair Removal Skin Types Technology Safety 52

The Dermatology Digest

DECEMBER 20, 2023

Mr. Raducha-Grace recently served as Head of Clinical Partnerships at Harbor Health. Before Harbor Health, he led product and go-to-market functions for CVS’s kidney care and home business units. Secondary measures of efficacy, as well as safety and pharmacokinetics, will also be assessed. Billingsley, MD.,

Dermatology 36

Dermatology Surgery Eczema Office 36

California Skincare Supply

OCTOBER 14, 2021

Although market averages will vary based on your location, the national average cost of a professional microdermabrasion treatment in 2020 was $167 according to the American Society of Plastic Surgeons. Your Go-To Marketing Tagline for Estheticians Ready for precision exfoliation?

Microdermabrasion 52

Microdermabrasion Exfoliation Chemical Peels Esthetician 52

Kind of Stephen

APRIL 7, 2022

In a clinical trial ³ , the combination was shown to reduce acne faster and more effectively than each one alone. There are differences between formulas available on the market, so a flat-out rule of “never mix” is likely false. Why might someone want to use tretinoin and benzoyl peroxide together? on KindofStephen.

Pharmaceutical 40

Pharmaceutical Clinic Ingredients Safety 40

Aesthetics Advisor

AUGUST 18, 2023

and the Springfield Wellness Center that uses IV NAD+ as a clinical therapy. Overall, the clinical research and large volume of anecdotal evidence would suggest that NAD+ IV therapy can treat alcohol and drug addiction and Parkinson’s disease. Therefore, the frequency of dosing will vary from clinic to clinic but is usually irregular.

Therapy 36

Therapy Injections Safety Clinic 36

Aesthetics Advisor

JANUARY 7, 2024

Nattokinase and Nattozimes are two supplements that are often marketed for their ability to support cardiovascular health. This is why nattokinase is often marketed as a supplement that can help support cardiovascular health by reducing the risk of blood clots, to help lower cholesterol, reduce inflammation, and improve circulation.

Marketing 36

Marketing Management Consultation Consultations 36

Aesthetics Advisor

NOVEMBER 7, 2023

The drug has been used successfully to grow new teeth in mice and ferrets, with clinical trials expected to begin in humans in July 2024 to test the drug’s safety in healthy adults. Dr. Takahashi said that he and his team hope to bring the drug to market by 2030. Reposted from: [link]

Clinic 36

Clinic Hospital Injections Surgery 36

Aesthetic Advancements Institute (AAI)

JUNE 20, 2023

There is a new dermal filler on the market! Juvéderm’s® newest filler, Volux , has been approved by the FDA and is set to hit medical offices in early 2023. This new filler is designed to specifically target the jawline, an area of concern for many consumers seeking facial sculpting and contouring.

Training 36

Training Injections Medical Facials 36

The Dermatology Digest

AUGUST 30, 2023

I think the most clinically meaningful endpoint is the time to loss of none or mild.” According to Dr. Lain, the “median six-month duration” often is a return to baseline, not time to mild or moderate wrinkling, which may not be as clinically meaningful. “So But maybe it just takes some time for that to mature in the market.”

Wrinkles 36

Wrinkles Office Safety Clinic 36